The economics of treating stroke as an acute brain attack
- PMID: 19775424
- PMCID: PMC2761940
- DOI: 10.1186/1741-7015-7-51
The economics of treating stroke as an acute brain attack
Abstract
Currently, treatments for ischemic stroke focus on restoring or improving perfusion to the ischemic area using thrombolytics. The increased hospitalization costs related to thrombolysis are offset by a decrease in rehabilitation costs, for a net cost savings to the healthcare system. However, early treatment is essential. The benefit of thrombolysis is time-dependent but only a very small proportion of patients, 2%, are presently being treated with tPA. In the United States, if the proportion of all ischemic stroke patients that receive tPA were increased to 4, 6, 8, 10, 15, or 20%, the realized cost saving would be approximately $ 15, 22, 30, 37, 55, and 74 million, respectively. Being so, efforts should be made to educate the public and paramedics regarding early stroke signs. Furthermore, additional acute stroke therapy training programs need to be established for emergency departments. Finally, hospital systems need to be re-engineered to treat patients as quickly as possible in order to optimize thrombolytic benefit as well as maximize cost-effectiveness.
Similar articles
-
Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.Stroke. 2005 Nov;36(11):2500-3. doi: 10.1161/01.STR.0000185699.37843.14. Epub 2005 Oct 13. Stroke. 2005. PMID: 16224087
-
Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.Stroke. 2013 Aug;44(8):2269-74. doi: 10.1161/STROKEAHA.113.001295. Epub 2013 Jun 18. Stroke. 2013. PMID: 23780955
-
Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.Stroke. 2014 Jun;45(6):1791-8. doi: 10.1161/STROKEAHA.113.003874. Epub 2014 May 13. Stroke. 2014. PMID: 24876261 Free PMC article. Clinical Trial.
-
Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):513-22. doi: 10.1586/erp.09.63. Expert Rev Pharmacoecon Outcomes Res. 2009. PMID: 19941428 Review.
-
Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.Acta Neurol Taiwan. 2004 Sep;13(3):149-55. Acta Neurol Taiwan. 2004. PMID: 15508942 Review.
Cited by
-
Trends in Outcome and Hospitalization Cost among Adult Patients with Acute Ischemic Stroke in the United States.J Vasc Interv Neurol. 2015 May;8(2):19-23. J Vasc Interv Neurol. 2015. PMID: 26060524 Free PMC article.
-
Cost burden of neuroimaging during one-time admission for first-ever acute stroke in Nigeria.Neurosciences (Riyadh). 2018 Apr;23(2):122-128. doi: 10.17712/nsj.2018.2.20170404. Neurosciences (Riyadh). 2018. PMID: 29664453 Free PMC article.
References
-
- Centers for Disease Control and Prevention Prevalence of disabilities and associated health conditions among adults: United States, 1999. Morb Mortal Wkly Rep. 2001;50:120–125. - PubMed
-
- Adams HP, jr, Dams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:1056–1083. doi: 10.1161/01.STR.0000064841.47697.22. - DOI - PubMed
-
- Brott T. Thrombolysis for stroke. Arch Neurol. 1996;53:1305–1306. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical